Table 3.

Complications of therapy (UPDRS IV), UPDRS-I, ADL and H&Y stage at baseline (before LCIG treatment) and at each follow-up visit, without LOCF

	BL mean score ( ± SD) (Range)	N	Visit 2	N	Visit 3	N	Reduction at V3 vs BL	*p value at V2 vs BL **p value at V3 vs BL	p ANOVA for repeated measures
UPDRS IV total score (Items 32–42)	8.2 (3.27) (0–18)	134	4.7 (2.88) (0–14)	124	4.9 (3.12) (0–14)	112	− 40%	* < 0.001 ** < 0.001	< 0.001
Dyskinesia duration (Item 32)	1.8 (1.04) (0–4)	134	1.2 (0.89) (0–4)	127	1.3 (1.02) (0–4)	113	− 28%	* < 0.001 ** < 0.001	< 0.001
Dyskinesia disability (Item 33)	1.5 (1.11) (0–4)	133	0.9 (1.02) (0–4)	124	0.9 (1.01) (0–4)	112	− 40%	* < 0.001 ** < 0.001	< 0.001
Painful dyskinesia (Item 34)	0.8 (0.97) (0–4)	133	0.4 (0.69) (0–4)	124	0.4 (0.73) (0–4)	112	− 50%	* < 0.001 ** < 0.001	< 0.001
Presence of early morning dystonia (Item 35)	58 (44%) (0–1)	133	35 (28%)	127	28 (25%)	113	− 43%	*0.002 ** < 0.001	< 0.001 (Logit)
OFF time duration (Item 39)	2.0 (0.81) (0–4)	137	0.9 (0.69) (0–3)	127	1.0 (0.75) (0–3)	114	− 50%	* < 0.001 ** < 0.001	< 0.001
UPDRS I total score
OFF	6.8 (4.75) (0–16)	79	5.9 (3.86) (0–16)	81	6.0 (3.71) (1–16)	65	− 12%	*0.054	0.006
ON	4.3 (3.08) (0–12)	96	3.6 (2.71) (0–12)	126	3.8 (2.78) (0–12)	110	− 12%	**0.055	0.008
UPDRS II (ADL) total score
OFF	29.2 (9.63) (0–48)	97	25.7 (8.49) (8–43)	86	25.5 (8.76) (8–46)	72	− 13%	* < 0.001 **0.003	< 0.001
ON	18.2 (9.39) (0–39)	111	16.2 (8.49) (1–43)	127	16.2 (8.45) (1–34)	109	− 11%	*0.003 **0.078	< 0.001
UPDRS V (Hoehn and Yahr)
OFF	3.99 (0.82) (2–5)	120	3.59 (0.85) (1–5)	100	3.7 (0.81) (2–5)	88	− 7%	*< 0.001 **0.003	< 0.001
ON	3.07 (0.75) (1–5)	135	2.72 (0.77) (0–5)	128	2.77 (0.83) (0–5)	115	− 10%	* < 0.001 ** < 0.001	< 0.001

ADL activities of daily living, BL baseline, LCIG levodopa/carbidopa intestinal gel, SD standard deviation; UPDRS, United Parkinson’s Disease Rating Scale